We are live on ! Find out more
AKBA icon

Akebia Therapeutics

157 hedge funds and large institutions have $100M invested in Akebia Therapeutics in 2026 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 40 increasing their positions, 55 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more call options, than puts

Call options by funds: $726K | Put options by funds: $463K

4% more capital inflows, than outflows

Capital inflows: $17.4M | Capital outflows: $16.7M

0.98% less ownership

Funds ownership: 40.24% → 39.26% (-0.98%)

8% less funds holding

Funds holding: 170 → 157 (-13)

27% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 55

42% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 38

Holders
157
Holders Change
-13
Holders Change %
-7.65%
% of All Funds
1.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
40
Reduced
55
Closed
38
Calls
$726​K
Puts
$463​K
Net Calls
+$263​K
Net Calls Change
+$118​K

AKBA Hedge Fund Activity: Q3 2026 in Review

157 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2026, worth a combined $100M — down 19% from $123M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of AKBA and 22 opened new positions — a net loss of 16 holders — while 55 trimmed existing stakes and 40 added.

The largest buyer was Acadian Asset Management, adding an estimated $5.34M. The largest seller was AQR Capital Management, cutting an estimated $3.07M.

  • 157 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2026, down from 170 in Q2 2026.
  • Funds reported $100M of Akebia Therapeutics stock for Q3 2026, down 19% quarter-over-quarter.
  • 22 funds opened new Akebia Therapeutics positions in Q3 2026 and 38 closed out, a net change of -16 holders.
  • The largest Akebia Therapeutics buyer in Q3 2026 was Acadian Asset Management, an estimated $5.34M added.
  • The largest Akebia Therapeutics seller in Q3 2026 was AQR Capital Management, an estimated $3.07M sold.

Based on aggregated 13F filings for Q3 2026.